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Abstract
The prevalence of common chronic non-communicable diseases (CNCDs) far overshadows the prevalence of both
monogenic and infectious diseases combined. All CNCDs, also called complex genetic diseases, have a heritable genetic
component that can be used for pre-symptomatic risk assessment. Common single nucleotide polymorphisms (SNPs) that
tag risk haplotypes across the genome currently account for a non-trivial portion of the germ-line genetic risk and we will
likely continue to identify the remaining missing heritability in the form of rare variants, copy number variants and
epigenetic modifications. Here, we describe a novel measure for calculating the lifetime risk of a disease, called the genetic
composite index (GCI), and demonstrate its predictive value as a clinical classifier. The GCI only considers summary statistics
of the effects of genetic variation and hence does not require the results of large-scale studies simultaneously assessing
multiple risk factors. Combining GCI scores with environmental risk information provides an additional tool for clinical
decision-making. The GCI can be populated with heritable risk information of any type, and thus represents a framework for
CNCD pre-symptomatic risk assessment that can be populated as additional risk information is identified through next-
generation technologies.
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Introduction
Common chronic non-communicable diseases (CNCDs) are
caused by a combination of genetic and environmental risk factors.
These diseases account for the majority of disease burden, and the
majority of health care cost, globally. Pre-symptomatic risk
assessment of an individual for CNCDs, and personalized
management to extend the healthy lifespan and reduce costs, is
increasingly a global priority [1]. CNCDs include diseases that are
not monogenic in nature, not purely environmental (trauma), and
not purely somatic. They do include the most common forms of
disease such as heart disease, metabolic disorders, neurological and
mental health disorders, heritable cancers, and many non-
congenital/non-monogenic pediatric disorders. Examples include
myocardial infarction, arrhythmia, diabetes, Alzheimer’s disease,
prostate cancer, and autism spectrum disorder.
Recent advances in genotyping technology have greatly
improved our understanding of the genetic risk factors that
contribute to such diseases. In particular, whole-genome associ-
ation studies have uncovered many common variants that increase
an individual’s risk of developing a disease during his/her lifetime.
Since disease prevention will be the most effective means to ensure
a healthier population in the coming decades, it is necessary to
understand how to integrate inherited genetic risk information into
our clinical decision-making process early in life so that we can
minimize the chance of developing disease in the future. Low
effect size common SNP variants, rare and private variants, DNA
copy number variants and epigenetic modifications are together
believed to account for most of the inherited risk. When we can
fully articulate the relative contribution of each of these elements
to any specific disease, and the effects of their interactions with one
another, our predictive accuracy will peak.
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Accurately estimating an individual’s risk to develop a CNCD is
a challenging task. To begin, the risk is determined by many
factors including the genetic risk factor load, environmental
factors, gender, age etc and not all contributing factors are known.
It is therefore clear that for most conditions the best risk
assessments can only provide a probabilistic estimate. In order
to accurately estimate the risk of an individual, one has to take into
account the different associated variants, their effect sizes, their
frequency in the population, the environmental factors affecting
the individual, such as diet, age, family history and ethnic
background as well as their interactions. Large-scale studies that
investigate all of these factors at once are prohibitively expensive to
conduct, and to our knowledge, none have been conducted.
Here, we study the performance of risk estimates based on the
genetic composition of an individual alone, keeping all other
factors fixed. Several approaches for risk estimation based on
genetics alone have been proposed in the past [2–4]. These
methods generally use the assumption that the disease-associated
loci are independent of one another and that the relative risk of
each locus is given. In practice, the relative risks are normally not
known since in case-control studies, the odds-ratios and not the
relative risks are given. In [2], the relative risks are inferred from
the odds ratios by solving a set of equations that takes into account
the prevalence of the disease, the frequencies of the genotypes and
the odds ratios. Here, we suggest using a new method which aims
at estimating the risk over the lifetime of an individual. The
probability of disease as calculated using our method will be
referred to as the Genetic Composite Index (GCI) or the GCI
score (see Methods).
Similarly to previous approaches, we rely on several assump-
tions, main among them being the assumption of independence
between the disease-associated loci. We use simulated data as well
as real data to assess the performance of the risk estimates under
different conditions. Importantly, we find that the assumption of
independence does not greatly affect the generality of our method
and modest SNP-SNP interactions in simulated data do not seem
to significantly affect its predictability.
In order to measure the quality and effectiveness of GCI and
similar methods, it is important to understand their limitations and
merits. For example, [2] use Receiver Operating Characteristic
(ROC) curves in order to measure the effectiveness of various risk
measures. We adapt their use of ROC curves to evaluate our
proposed score, and in particular, we consider the use of GCI in
the context of three different diseases: Type 2 Diabetes, Crohn’s
disease and Rheumatoid Arthritis. We use simulations to calculate
the predictive power of these different methods under an ideal
‘‘best-case’’ theoretical scenario, in which all the genetic factors are
known. This ideal risk assessment depends on several factors
including the heritability and the average lifetime risk of the
disease. We find that the predictive power currently achieved for
these diseases is substantially lower than the ideal predictive
power, suggesting that major interactions and possible epigenetic
factors are yet to be discovered. We emphasize that GCI is not a
substitute for large-scale studies designed to simultaneously test
multiple risk factors, but is rather an index that can be used when
the result of such studies are simply not available, as is the case for
virtually all common diseases.
Results
Evaluation of the GCI risk score and its assumptions
We use the Wellcome Trust Case Control Consortium
(WTCCC) data [5] to test our GCI methodology. This dataset
contains the genotypes of approximately 14,000 individuals
divided into seven subpopulations based on disease phenotypes
and one unaffected control subpopulation of 1,500 samples from
the UK Blood Service Control Group. We limited our attention to
the Type 2 Diabetes, Crohn’s Disease and Rheumatoid Arthritis
subpopulations and the common control group and did not
consider any environmental variables in this analysis. We used
SNPs that were reported to be significantly associated with each of
these conditions in literature (see Table 1) and that passed a set of
quality criteria. The main criteria were that i) The SNP association
was consistently replicated within a given ancestral group and ii)
The number of cases and controls were at least 250 when the effect
size was less than 1.5 (Details about genotyping quality criteria in
WTCCC data are given in [5]. There are no other criteria with
respect to genotyping except that the SNPs chosen were reported
in high quality studies that use good genotyping methodology). For
each of the chosen SNPs, we computed the relative risk (see
Methods) based on the empirical distribution of alleles found in the
WTCCC dataset and used the GCI formula to calculate an
estimated risk per individual. We note that some of the known risk
variants are not present on the Affymetrix 500k GeneChip array
that was used by the WTCCC, and therefore we expect the
predictability of the GCI to be better than what is presented in our
analysis below.
As noted before, we use Receiver Operating Characteristic
(ROC) curve analysis [12] in order to evaluate the ability of GCI
to serve as a predictive test for a condition. ROC curves have been
previously used as a measure of the reliability of a genetics-based
risk assessment test [2]. For a perfect test, a threshold t could be
chosen such that all individuals with a score larger than t develop
the condition, and all individuals with a score less than t don’t.
However, in practice, we will find that for any given threshold
there is some fraction of false positive and false negative
assignments. The ROC curve graphically depicts the relationship
between false positive rates and true positive rates, and thus it can
be used to guide the tradeoffs between test sensitivity and
specificity. We use the area under the ROC curve (AUC) as a
quantitative measure to compare different risk scores. In general,
the larger the value of the AUC, the better the score used for the
classification. If classification were done randomly, the AUC is
expected to be 0.5 and for the perfect score the AUC is equal to 1.
Comparisons with an interactions model
One of the assumptions made by the GCI framework is that the
disease-associated SNPs are independent. This assumption is
useful since the score can then be calculated just from summary
data; furthermore, when interactions are modeled based on
limited data, there is a risk of over-fitting. Nevertheless, in an
attempt to quantify how much information might be lost by the
independence assumption, we compared our method with a model
that accounts for both SNP-SNP interactions and the marginal
contribution of each SNP. Particularly, we used logistic regression
to account for the interactions. If the SNPs are s1, s2…sn, then the
model assumes that the logit transformation of the binary outcome
reflecting disease or non-disease status is X~ cza1s1z a2s2
z . . .zansnz a12s12z . . .zan{1,nsn{1,n, where sij is the inter-
action between si and sj. We first trained the model using the
WTCCC data and then generated a ROC curve based on its
probability estimates. Since this model takes into account the pair-
wise interactions between SNPs, it should be at least as accurate as
the GCI score, which does not consider them. Note that the
logistic regression model is an optimistic upper bound on the GCI
since it can easily over-fit the model to the data; therefore, we are
being conservative in our estimation of the information lost under
the independence assumption. Figure 1 shows the ROC curves
Lifetime Disease Risk
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14338
Table 1. Allele frequencies and the relative risks of Type 2 Diabetes, Crohn’s Disease and Rheumatoid Arthritis SNPs.
Disease dbSNP rs id Relative risk1 for RR Relative Risk1 for RN Frequency2 of RR Frequency2 of RN
Type 2 Diabetes rs10012946 [6] 1.1464 1.0239 0.5000 0.4667
rs10811661 [7] 1.3008 1.1282 0.6667 0.2500
rs1801282 [7] 1.4128 1.2417 0.8667 0.1167
rs4402960 [7] 1.1602 1.1233 0.1167 0.3500
rs4506565 [5] 1.6133 1.2738 0.0847 0.3729
rs5215 [7] 1.1681 1.0935 0.1000 0.6167
rs8050136 [8] 1.3609 1.1176 0.1167 0.6667
rs9494266 [9] 1.4909 1.2296 0.0169 0.0847
rs10923931 1.1948 1.0947 0.0167 0.2000
rs4607103 1.1392 1.0681 0.6333 0.3500
rs7961581 1.1355 1.0664 0.0500 0.3667
rs864745 1.1530 1.0747 0.3158 0.4035
rs5015480 1.1456 1.0451 0.3167 0.4833
Crohn’s Disease rs10883365 1.6154 1.1989 0.3000 0.4000
rs2066845 11.4381 3.0164 0.0000 0.0333
rs10489276 1.4130 1.1888 0.0333 0.3667
rs1894603 1.4608 1.2088 0.2542 0.4407
rs4871611 1.1654 1.0795 0.3667 0.5000
rs6679677 1.7116 1.3085 0.7167 0.2833
rs17234657 2.3052 1.5360 0.0667 0.2000
rs11175593 2.3532 1.5353 0.0000 0.0333
rs11584383 1.3899 1.1790 0.4333 0.4500
rs1456893 1.4371 1.1989 0.3667 0.5333
rs1736135 1.3898 1.1790 0.3000 0.5000
rs17582416 1.3432 1.1590 0.1667 0.4333
rs2872507 1.2527 1.1193 0.2167 0.5000
rs3764147 1.5580 1.2484 0.0847 0.3220
rs4263839 1.4852 1.2188 0.4167 0.4667
rs744166 1.3898 1.1790 0.3276 0.4483
rs762421 1.2751 1.1292 0.2500 0.4833
rs10210302 1.8433 1.1890 0.3000 0.5000
rs7746082 1.3663 1.1690 0.1017 0.4915
rs7927894 1.3432 1.1591 0.2333 0.3833
rs9858542 1.8316 1.0895 0.0333 0.4167
rs11805303 1.8525 1.3875 0.1000 0.3833
rs1000113 1.9102 1.5354 0.0000 0.0667
rs2066844 3.2543 1.9609 0.0000 0.2203
rs17221417 1.9118 1.2883 0.1000 0.5167
rs2542151 1.9997 1.2980 0.0500 0.2833
rs10761659 1.5461 1.2287 0.2333 0.6333
Rheumatoid rs10118357 [10] 1.7278 1.3152 0.2712 0.5254
Arthritis rs13207033 [10] 1.7559 1.3258 0.6667 0.3167
rs6457617 [5] 5.0847 2.3414 0.2167 0.5667
rs6679677 [11] 3.1672 1.6847 0.0000 0.2833
rs6920220 [5] 1.7023 1.1965 0.0000 0.3500
1. The relative risks provided here were calculated using the GCI methodology, as explained in the Methods section. RR means risk-risk genotype and RN means risk-
nonrisk genotype.
2. The allele frequencies are taken from the HapMap project’s CEU population.
doi:10.1371/journal.pone.0014338.t001
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for the three disease scenarios and Table 2 gives their AUCs. We
observe that the AUCs for GCI and logistic regression are quite
similar for these three diseases, leading us to the conclusion that
SNP-SNP interactions do not add substantial information to the
risk assessment for the diseases investigated here. We can therefore
justify our assumption (at least in these cases) that SNP-SNP
interactions can be ignored as long as there is no evidence for such
an interaction from previous studies.
Theoretical upper bound for disease-risk predictability
The number of SNPs used in our analysis reflects the current
knowledge about the effect of common SNPs on the risk of a
disease. These, however lack many other factors such as epigenetic
factors, rare variants, copy number variants, interactions etc. The
question remains as to how much more accurate could we
potentially be when considering genetic factors alone. We shed
light on this by comparing our empirical results to theoretical
disease models that assume that the disease is affected by both
environmental and genetic factors, and that the two factors are
independent (see Methods). Our model assumes that there are
many small genetic effects that are cumulative and therefore the
genetic factors include a normally distributed random variable. It
takes into account the heritability and lifetime risk of the condition,
resulting in a realistic extrapolation of the unknown genetic risk
factors based on the currently known ones.
Formally, the theoretical model uses a phenotype variable P,
and it assumes that P~Gz E, where G is the genetic risk and E
is the environmental risk and an individual will develop the
condition in his/her lifetime if Pw bfor a fixed b (see Methods for
more details). We generated 100,000 random samples for the
distribution of P based on our theoretical models for G and E and
determined their disease status. We then assumed that G is known
for each individual (but E is unknown), and generated a ROC
curve for the samples using this information alone. This curve
represents an optimal scenario where the genetic risk is entirely
understood and can be measured correctly for every individual but
environmental risk factors are completely unknown. We will refer
to the area under the ROC curve in this case as the theoretical
genetic maximum. Figure 1 shows the ROC curves for such a
scenario and Table 2 gives their areas. We observe that the GCI
area under the curve with currently known variants is much less
than that of the optimal theoretical genetic models, which suggests
that many additional unknown genetic variants and/or interac-
tions are expected to affect these diseases.
Based on Figure 1, we conclude that there is room for
improvement in predictive modeling that will most likely come
through the discovery of additional genetic variants and gene-
environment interactions for the three conditions discussed in this
text. It is useful to know what percentage of the genetic factors
have been captured to date. Under the assumption that all the
major genetic factors have already been discovered and that there
are no gene-gene or gene-environment interactions, we can
estimate the number of variants that will suffice to obtain a ROC
curve with an AUC as large as the theoretical genetic maximum. If
we assume that the GWAS studies performed to date have
sufficient density to identify all large effect size common variants in
Figure 1. ROC curves for the WTCCC dataset. A. Crohn’s Disease.
B. Type 2 Diabetes. C. Rheumatoid Arthritis. In each plot, the black line
corresponds to random expectation, the blue lines correspond to
theoretical expectations (under the two disease models described in
Methods) when the genetic variable is known, the red line corresponds
to GCI, and the green line corresponds to logistic regression.
doi:10.1371/journal.pone.0014338.g001
Lifetime Disease Risk
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the genome, and that all the unknown variants are common
(minor allele frequency = 10%), yet of weak effect size and that
such variants contribute relative risks of 1.1 for the homozygous
risk genotype and 1.05 for the heterozygous genotype; then our
results show that under these assumptions the number of
undiscovered risk factors is quite large (in the 1000s). Furthermore,
we observe that only about 6% of the genetic variance is explained
by the known variants for Type 2 Diabetes, about 9% for Crohn’s
disease, and about 14% for rheumatoid arthritis. It is also
reasonable to assume that additional large-effect size variants will
be discovered through the use of next-generation technologies and
take the form of rare/de novo nucleotide variants, copy number
variants and epigenetic modification of the primary nucleotide
sequence – and that it is likely that a blend of a few of these larger
effects will account for the missing heritability together with a
larger number of common and weak effect size variants.
Attempts to estimate the number of causal variants in complex
diseases have been made in the past [19–21]. These attempts
reach somewhat different conclusions than ours, i.e. these studies
estimate the number of genetic effects to be found to be quite
modest, even under the assumption of independence between
genes and environment. The main difference in the methodology
between our approach and these previous approaches is that
previous approaches have been published prior to the results
achieved by GWAS studies. Thus, they do not make the
assumption that the major common effects have already been
found, and they do not take into account the heritability and
lifetime risk. We note that [22] used a model similar to ours to
investigate the relationship between the number of disease loci and
the relative risk of the loci and their results are broadly similar to
ours. They use the prevalence of the disease instead of lifetime risk.
It must be mentioned that inaccuracies in the heritability estimates
can affect these numbers, but as long as they are not off by an
order of magnitude, we expect the results to be qualitatively
similar.
Theoretical effect of unknown SNP-SNP interactions
Our GCI score is based on the assumptions that all SNPs are in
linkage equilibrium and that they have independent effects on the
risk of the disease. As discussed above, the three examples studied
here show no significant difference between the GCI model and a
model in which pair-wise dependencies among the SNPs are
included through logistic regression. This assumption may not
always hold since, we know of some rare examples for which there
is evidence of epistasis [23]. If these interactions are known, they
can easily be incorporated into the GCI model by considering the
interacting SNPs together as a combination. However, it is
important to understand the effect of unknown SNP-SNP
interactions on the multiplicative risk estimates.
In order to further explore the issue of interactions, we
simulated datasets under a model in which a single pair of SNPs
is interacting. Formally, the model can be described as follows. Let
li denote the relative risk of the disease for a particular
combination of genotypes (gi) and p denote the average lifetime
risk. If all SNPs are independent, the total risk is proportional to
li~ P
n
j~1
lijwhere lij denotes the relative risk for the j
th locus. In
the interactions model, we assume that for a particular pair, the
relative risk for some combinations of genotypes is c times larger
than the product of their relative risks. For all other SNPs and for
all other genotype combinations, relative risks are assumed to be
multiplicative. Thus, for example, if SNPs x and y interact, then
the relative risk for the pair, K~ clixliyfor certain configurations
of (gix, giy), andK~lixliyfor other combinations. The total risk in
this case would be K P
n
j1x,j1y
lij.
We set the values of lix, liy for the interacting SNPs x and y so
that the relative risks for each of these SNPs under univariate
models is equal to what is observed in real data (given in Table 1).
We assign the probability that an individual is a case to be
P (disease j gi)~Cli, where C is a normalizing factor, and li is
the relative risk of individual i based on the interactions model. We
choose C so that the fraction of cases is close to the average
lifetime risk of the disease.
Let RR, RN and NN denote the observed values of relative risks
for any SNP for risk-allele homozygote (2), heterozygotes (1) and
non-risk-allele homozygote (0) respectively and let rr, rn and nn
denote the respective genotype frequencies. Since lij for any locus
j can only take 3 possible values corresponding to the 3 possible
genotypes, we will denote these by lij0, lij1, and lij2 respectively
and set lij0~ 1for all SNPs. We obtain values of lix1, liy1, lix2,
liy2 for SNPs x and y by solving the following system of equations:
RRx ~ (crrylix2liy2 z crnylix2liy2 z
nnylix2)=(rryliy2z rnyliy1 z nny)
RNx ~ (crrylix1liy2 z crnylix1liy1 z
nnylix1)=(rryliy2z rnyliy1 z nny)
RRy ~ (crrxliy2lix2 z crnxliy2lix1 z
nnxliy2)=(rrxlix2z rnxlix1 z nnx)
RNy ~ (crrxliy1lix2 z crnxliy1lix1 z
nnxliy1)=(rrxlix2z rnxlix1 z nnx)
Based on the risks in the interactions model, we assigned disease
status labels for 100,000 randomly drawn samples. We used this
Table 2. The area under the ROC curve for the three diseases under three different scenarios.
Disease Heritability Average Lifetime Risk Optimal Scenario1 GCI score Logistic Regression
Type 2 Diabetes 64% [13] 25.0% [16] 0.894 0.613 0.644
Crohn’s Disease 80% [14] 0.56% [17] 0.992 0.689 0.757
Rheumatoid Arthritis 53% [15] 1.54% [18] 0.944 0.675 0.689
1. The ideal score when the complete genetic information is known.
doi:10.1371/journal.pone.0014338.t002
Lifetime Disease Risk
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simulated case-control data to plot ROC curves based on two
approaches for risk assessment. First, we calculate the relative risk
of an individual according to the true interactions model. Then,
we assigned relative risks assuming the independence model. As
observed in Figure 2 and in Table 3, we find that the ROC
curves can differ marginally when the interaction factor is high (i.e.
c=10). However, it can be argued that strong deviations from the
independence model will also be more detectable in genome wide
association studies. Particularly, whole-genome association studies
often report that SNP-SNP interactions were tested but were not
found to be significant (e.g. [24]). Therefore, when no interactions
have been reported in the literature for a set of SNPs, it seems
unlikely that the classification accuracy of the multiplicative test
will differ dramatically from that of the true model that includes
interactions.
Measuring the Absolute Error in the Risk Estimate
The ROC curve serves as one metric for evaluating a diagnostic
in that it provides a quantitative measure of the ability of the test to
distinguish between unaffected and affected individuals. However,
when estimating the lifetime risk, the ROC curve alone may not
be sufficient if a score does not directly estimate the correct
probabilistic measure (i.e. the probability of developing disease in
one’s lifetime) but instead computes some function of this
probability. In particular, for any given pair of score functions,
f1(G) and f2(G), the ROC curves of the functions will be identical
as long as f1 is a monotonic increasing function of f2. For instance,
we could simply assign f2(G)~ log(f1(G)), and in this case by
using the scores f1 and f2 to estimate risk we will get exactly the
same ROC curves. However, these two functions may give very
different lifetime risk estimates to individuals. Therefore, ROC
curves alone are not sufficient for tests that report probabilistic
risk. For quality assessment, we also need a more informative
quantity, the absolute value of relative error between the true risk
probability and the estimated risk probability. The relative error is
defined as the difference between the estimated and true risk
probability divided by the true risk probability. Thus, the absolute
value of relative error is given by:
jEstimatedRisk Probability -TrueRisk Probabilityj=
TrueRisk Probability
Since the true probability of developing a disease is unknown,
we simulated a scenario in which case-control data is used to
calculate the GCI parameters (i.e. the relative risks), and then
applied the GCI risk estimates to another independently simulated
population. The disease model we used for the simulation assumes
that the genetic factors of the disease can be decomposed into a
small number of large effects and a large number of small effects
that can be approximated by a normal distribution (see Methods).
Since most diseases are diagnosed later in life, we introduced the
age of onset of the disease to the model. For each individual that
has been determined to develop the disease based on the model,
we choose the age of onset of the disease based on some
distribution for the age of onset (Normal distribution with mean
= 50 and SD =13). Thus, in our simulation, some of the controls
may in fact be cases that have not been diagnosed at the time of
the study. To create a realistic simulation of an age-matched case-
control study, we first repeatedly simulated the genetic and
environmental factors, as well as the age of onset for individuals;
we picked the age of the individuals from a uniform distribution
between 0 and 100. We generated 10,000 cases using this process.
For each of these cases, we generated an age-matched control by
sampling 10,000 controls conditioned on their age. We estimated
the odds ratios for each SNP based on this case-control data, and
then used these odds ratios to calculate the relative risks for each
SNP associated with the disease, using our GCI methodology.
The above procedure was used to generate a simulated set of
relative risk values. We then generated 500 individuals randomly
according to the theoretical disease model. Since the variables are
known for each of these individuals, we know the correct genetic
risk to develop the condition. We use these ‘true risks’ as a baseline
for the accuracy measure. We compare the GCI based risk
estimates to this baseline, as well as a variant of the GCI in which
the relative risks are replaced by the odds ratios. We note that
methods that calculate disease risk based on prevalence (e.g. [2])
will usually get relative risks that are close to the odds ratios.
In Figure 3, we plot the distribution of the absolute value of
relative errors for a simulated disease with average lifetime risk of
25% and heritability of 64% (Figure 3a), and for a disease with
average lifetime risk of 42% and heritability of 57% (Figure 3b).
These values roughly correspond to the lifetime risk and
heritability of Type 2 Diabetes and Myocardial Infarction
respectively. It is clear from the Figure that there is a dramatic
difference between the lifetime risks when using the relative risks
and when using the odds ratios. This may not be noticeable using
a ROC curve that only measures the classification accuracy. Thus,
using odds ratios or prevalence based calculation for relative risk
Table 3. The area under the curve (AUC) for the different interaction scenarios.
Simulated Interaction Factor 21 Simulated Interaction Factor 102
Interaction risk estimate GCI risk estimate (Multiplicative) Interaction risk estimate GCI risk estimate (Multiplicative)
Crohn’s Disease 0.722 0.722 0.739 0.724
Rheumatoid Arthritis 0.679 0.674 0.720 0.673
Type 2 Diabetes 0.597 0.594 0.607 0.595
1. The two columns correspond to the case where there is a SNP-SNP interaction in which the effect of a certain combination of genotypes has two times the product of
the marginal effects.
2. The two columns correspond to the case where there is a SNP-SNP interaction in which the effect of a certain combination of genotypes is 10 times the product of
the marginal effects.
doi:10.1371/journal.pone.0014338.t003
Figure 2. ROC curves for models with interactions vs the simple multiplicative model. A. Crohn’s Disease. B. Rheumatoid Arthritis. C. Type
2 Diabetes. In each plot, 1,000 threshold points were used.
doi:10.1371/journal.pone.0014338.g002
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generally inflates the results for lifetime risk calculations, and
under some circumstances can generate lifetime risk estimates that
are larger than 100% (hence these are not good enough for
lifetime risk calculations and our methodology is necessary).
Can the addition of environmental risk factors improve
our current predictions?
In the previous sections, we used only the genetic information to
estimate the risk of disease. In order to estimate the potential
contribution of known environmental factors to disease prediction,
we now consider the case where both environmental and
genotypic data are used to estimate risk. Such an example was
studied for the case of Type 2 Diabetes in [2]. Here, we
demonstrate the utility of environmental factors across Type 2
Diabetes, Crohn’s Disease and Rheumatoid Arthritis, which have
very different heritability and average lifetime risk values. As in
[2], we also assume that the risks and frequencies across all SNPs
as well as across all environmental factors are independent and
multiplicative. Based on this assumption, we generalized the GCI
score for the case where environmental factors are also taken into
account. We call the resulting statistic for lifetime risk Environ-
mental-Genetic Composite Index (EGCI). The EGCI score (like
the GCI score) is defined as the product of relative risks across all
the markers and all of the environmental factors normalized by a
constant. Note that when calculating the EGCI, the different
levels/classes of any particular environmental factor are treated in
exactly the same way as the different alleles of a marker in GCI.
Thus, environmental factors are mathematically no different from
additional markers. Table 4 gives the frequencies and relative
risks of the environmental variables for the 3 diseases.
We simulated the genotype and environmental factor values for
a set of 100,000 individuals based on their known frequencies in
the population (See Tables 1 and 4). For every individual, we
randomly and independently generate each genotype and
environmental variable using these frequencies (In particular, we
use a uniform random number between 0 and 1 for doing this).
We then randomly assigned a disease status for all individuals
based on the lifetime risk probabilities calculated from the
generalized multiplicative model (i.e. EGCI). Next, we compared
the predictive power of the pure genetics based GCI score to the
new generalized EGCI score. The ROC curves for Type 2
Diabetes, Crohn’s Disease and Rheumatoid Arthritis are shown in
Figure 4. The added value of environmental factors is not
dramatic for Crohn’s Disease and Rheumatoid Arthritis, however
it is substantial for Type 2 Diabetes. This is driven by the fact that
Body Mass Index is crucially affecting the risk for Type 2 Diabetes
(with a relative risk of 42.1 when BMI .35 [25]). Note that for a
disease such as Crohn’s disease we do not expect environmental
factors to play a major role since the heritability of this condition is
roughly 80%.
GCI and EGCI for Type 2 Diabetes case-control data from
the GENEVA study
GENEVA study refers to the Gene Environment Association
Studies initiative (www.genevastudy.org) funded by the trans-NIH
Genes, Environment, and Health Initiative (GEI). The goal of this
study is to identify novel genetic factors that contribute to Type 2
Diabetes Mellitus through a large-scale genome-wide association
study of well-characterized cohorts of nurses and health profes-
sionals. In this study, around 1 million SNPs have been genotyped
in about 2712 cases with Type 2 Diabetes and 3179 controls. A
variety of environmental variables have also been collected for
these individuals. We illustrate the performance of GCI and EGCI
methodology using 15 disease SNPs present in the GENEVA
dataset. We only used unrelated individuals of Caucasian ancestry
for this analysis. For calculating EGCI, we considered 2
environmental variables namely the Body Mass Index (BMI) and
the smoking status (Table 5 gives their relative risks). The results
obtained are shown in Figure 5 and the SNPs used are listed in
Table 6.
Discussion
The Human Genome Project [26], the HapMap project [27],
and related initiatives have resulted in a reference human
genome sequence, a catalog of common genetic variation and a
haplotype map of several reference populations. Furthermore, this
Figure 3. Relative errors for the estimated lifetime risk
probabilities. A. Comparison of odds ratios and relative risks for
Type 2 Diabetes with lifetime risk of 25% and heritability of 64%. B.
Comparison of odds ratios and relative risks for Myocardial Infraction
with lifetime risk of 42% and heritability of 57%.
doi:10.1371/journal.pone.0014338.g003
Lifetime Disease Risk
PLoS ONE | www.plosone.org 8 December 2010 | Volume 5 | Issue 12 | e14338
information combined with cost-effective technologies to test
associations between variations throughout the genome and traits
and diseases of all sorts, has resulted in dozens of common variants
shown to be unequivocally statistically associated with the risk of
common diseases. These common variants can be used much like
population-derived environmental risk factor data in assessing
probabilistic pre-symptomatic risk of disease.
We have presented a new method for the estimation of an
individual’s lifetime risk based on genetic data through a genetic
score function (the GCI). The GCI, like all estimates of a
particular quantity, requires a set of assumptions that may bias the
risk estimates. Particularly, the assumptions made by the GCI
score are that the allele frequencies of the causal SNPs and effect
sizes are known, and that all the SNPs are independent of each
other. We show through simulation studies and by the analysis of
the WTCCC data that, moderate SNP-SNP interactions have
almost no effect on the power of the multiplicative GCI score.
However, in principle strong non-additive effects between variants
might affect the risk estimates, and thus care has to be taken when
interpreting the results. In most scenarios, we expect that such
effects will likely be discovered prior to the use of GCI and can be
incorporated in the risk calculation. So, we view this as a minor
problem, especially given that no significantly strong SNP-SNP
interactions have been uncovered in whole genome association
studies performed over the past several years.
We used the ROC curve analysis and the heritability of each of
the conditions we considered to find the total genetic variation
explained by known variants, compared to the expected genetic
variation based on heritability. We find that current scientific
knowledge can explain approximately 6%-14% of the total genetic
variation for these conditions. This suggests that the risk estimates
provided by the GCI may vary considerably in the future, as more
genetic variants are found and used for risk estimation (e.g. see
[24]). The fact that only a small fraction of the genetic variants
have been found to date suggests that the variance of the risk
calculated by the GCI is still large; however, the GCI score aims at
estimating the expected frequency of individuals with a given
genetic load that will develop the condition during their lifetime,
and the accuracy of the estimate of expectation will not be affected
by the number of unknown variants.
It is clear that next-generation technologies will be used in study
designs similar to GWAS to identify additional heritable risk factors
for CNCDs. As each new genetic association is validated to the
appropriate industry thresholds, this new genetic risk information
can be added into the GCI in a scalable fashion, on a disease-by-
disease basis to improve the accuracy of the GCI in real time.
Given these interpretations of the GCI score, it is informative to
use such a score in order to estimate the risk of an individual based
on their genetic data. The medical benefits of such individualized
knowledge are intuitive, but have to be clinically proven through
prospective studies. The main open question is whether individuals
will benefit by change of behavior, early diagnosis or an
individualized course of treatment based on their genetic
information for actionable CNCDs. We believe that tools such
as the GCI score will facilitate such studies and help transition us
into the era of personalized preventive medicine.
Methods
Ethics Statement
The datasets used were approved by the relevant boards in
Navigenics Inc and University of California Davis.
Introduction
We consider a disease for which k risk loci have been identified.
As done in [2,3], we assume that the different loci are acting
Table 4. Relative risks of environmental variables for Type 2 Diabetes, Crohn’s disease and Rheumatoid Arthritis.
Disease Environmental Variable Level
Proportion in the
population Relative risk
,23 0.20 1.00
23–23.9 0.16 1.00
24–24.9 0.14 1.50
25–26.9 0.27 2.20
Type 2 Diabetes Body Mass Index 27–28.9 0.14 4.40
29–30.9 0.06 6.70
31–32.9 0.02 11.6
33–34.9 0.01 21.3
.= 35 0.01 42.1
Never Smoked 0.50 1.00
Smoking Ex-Smoker 0.39 1.10
,20 cigs/day 0.04 1.50
.= 20 cigs/day 0.07 1.70
Never Smoked 0.545 1.00
Crohn’s Disease Smoking Ex-Smoker 0.245 1.70
Current-Smoker 0.198 3.00
Never Smoked 0.498 1.00
Rheumatoid Arthritis Smoking Ex-Smoker 0.276 1.40
Current-Smoker 0.227 1.30
doi:10.1371/journal.pone.0014338.t004
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independently, and thus Pr(g1, . . . ,gkjD)~ P
k
i~1
Pr(gijD), and
Pr(g1, . . . ,gk)~ P
k
i~1
Pr(gi), where gi is genotype of an individual
in locus i, and D represents the event that the individual will
develop the disease across his or her lifetime. As noted by [2], it is
straightforward to extend this model to cases where some
interactions are known. Previous methods consider D as the event
that the individual is currently diseased and thus the risk estimated
by these methods is for a snapshot in time. Such risk is related to
the overall lifetime risk of the disease but with obvious differences.
This difference can be quite dramatic in some cases, as we show in
the results section.
When calculating the risk across multiple SNPs for an individual
with genotypes (g1,…,gn), we are interested in finding the
probability Pr(Djg1, . . . ,gn). Using Bayes law and the indepen-
dence assumption
Figure 5. ROC curves for the GENEVA dataset. Effect of genetic
(15 SNPs given in Table 6) and environmental factors (BMI, Smoking)
versus genetic factors alone for predicting Type 2 Diabetes in 2600
cases and 3000 controls in the GENEVA data. The AUCs of the two
curves are 0.727 and 0.565 respectively. The relative risks for BMI and
Smoking are given in Table 5.
doi:10.1371/journal.pone.0014338.g005
Figure 4. EGCI vs. GCI in simulated data. A. Effect of known
genetic and environmental factors versus known genetic factors alone
for Crohn’s Disease. The AUCs of the two curves are 0.74 and 0.78. We
considered smoking as the environmental variable in addition to the
genetic factors. B. Effect of known genetic and environmental factors
versus known genetic factors alone for Type 2 Diabetes. The AUCs of
the two curves are 0.58 and 0.79 respectively. We considered Body Mass
Index, alcohol intake and smoking frequency as the environmental
factors for Type 2 Diabetes, in addition to the genetic factors. C. Effect
of genetic and environmental factors versus genetic factors alone for
Rheumatoid Arthritis. The AUCs of the two curves are 0.685 and 0.690.
We considered smoking as the environmental variable in addition to
the genetic factors. The relative risks for the environmental variables are
provided in Table 4.
doi:10.1371/journal.pone.0014338.g004
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Pr(Djg1, . . . ,gn)~
Pr(g1, . . . ,gnjD)Pr(D)
Pr(g1, . . . ,gn)
~
Pr(D) P
n
i~1
Pr(gijD)
P
n
i~1
Pr(gi)
~
P
n
i~1
Pr(Djgi)
Pr(D)n-1
In order to estimate the lifetime risk of a specific individual, we
therefore need to have an estimate of the average lifetime risk
Pr(D) across the entire population and the risk of developing the
disease across the lifetime of an individual with genotype gi. The
former has been estimated for a wide range of conditions using
prospective studies [16–18]. The latter can be estimated using our
method from case-control studies as described below.
Odds ratios vs. relative risk
In epidemiology literature, the relative risk is often considered
an intuitive and informative measure of risk. The relative risk is
defined as li~
Pr(Djai)
Pr(Dja0), where a0, a1, and a2 correspond to the
genotypes with 0, 1, and 2 risk alleles. If the relative risks are
known, we could estimate Pr(D|ai) by using the following:
Pr(D)~Pr(D j a2)Pr(a2)z
Pr(D j a1)Pr(a1)zPr(D j a0)Pr(a0)
ð1Þ
Equation 1, together with the relative risks provide three
independent equations with three variables, since Pr(ai) can be
found by considering a reference population, and Pr(D) is known.
Unfortunately, the relative risk cannot be directly calculated in the
context of case-control studies and whole-genome association
studies. The relative risk can usually be estimated through
prospective studies in which a set of healthy individuals is studied
over a long period of time. In contrast, odds ratios are normally
reported in case-control studies. The odds-ratio is the ratio
between the odds of carrying the risk allele in cases vs. controls.
For rare diseases, the odds ratio is a good approximation of
relative risk; however for common diseases, the odds ratio could
result in a misleading estimate of risk, where the odds ratios may
be quite high even when the increase in risk is minor.
As previously noted [2], one can estimate the relative risks from
the odds ratios by solving a set of equations. However, the
equations proposed in [2] assume that the control population will
never develop the disease. In the context of lifetime risk estimation
this assumption is no longer valid since a subset of the control
population might eventually develop the disease.
Table 6. SNPs used when analyzing the GENEVA genotype data.
Disease dbSNP rs id Relative risk1 for RR Relative risk1 for RN Frequency2 of RR Frequency2 of RN
Type 2 Diabetes rs153143 1.1586 1.0772 0.0170 0.1670
rs11634397 1.0961 1.0472 0.3280 0.5340
rs8042680 1.1112 1.0545 0.0330 0.3670
rs10012946 [6] 1.1464 1.0239 0.5000 0.4667
rs10811661 [7] 1.3008 1.1282 0.6667 0.2500
rs1801282 [7] 1.4128 1.2417 0.8667 0.1167
rs4402960 [7] 1.1602 1.1233 0.1167 0.3500
rs4506565 [5] 1.6133 1.2738 0.0847 0.3729
rs5215 [7] 1.1681 1.0935 0.1000 0.6167
rs8050136 [8] 1.3609 1.1176 0.1167 0.6667
rs10923931 1.1948 1.0947 0.0167 0.2000
rs4607103 1.1392 1.0681 0.6333 0.3500
rs7961581 1.1355 1.0664 0.0500 0.3667
rs864745 1.1530 1.0747 0.3158 0.4035
rs5015480 1.1456 1.0451 0.3167 0.4833
1. The relative risks provided here were calculated using the GCI methodology, as explained in the Methods section. RR means risk-risk genotype and RN means risk-
nonrisk genotype.
2. The allele frequencies are taken from the HapMap project’s CEU population.
doi:10.1371/journal.pone.0014338.t006
Table 5. Relative risks of environmental variables for Type 2
Diabetes.
Disease
Environmental
Variable Level Relative risk
,23 1.00
.= 23 and ,25 2.67
Body Mass Index .= 25 and ,30 7.59
.= 30 and ,35 20.1
Type 2 Diabetes .= 35 38.8
Never Smoked 1.00
Smoking Ex Smoker 1.23
Current Smoker 1.44
doi:10.1371/journal.pone.0014338.t005
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Calculating Risk in the Presence of Diseased Controls
We now turn to the calculation of Pr(D|gi) given that an a
fraction of the controls will eventually develop the disease along
their lifetime. We consider a locus in which m+1 different alleles
are present. This allows us to deal with general scenarios, in which
gi may represent any number of interacting SNPs, and where
m=3s, where s is the number of SNPs represented by gi.
We will denote the m+1 possible alleles by a0, a1…, am, where
a0 is the non-risk allele, and their respective allele frequencies in
the general population as f0, f1,…, fm. Given that an a fraction of
the controls will eventually develop the condition, we can write the
odds ratios as:
ORi~
Pr(Djai)(aPr(Dja0)z(1{a)(1{Pr(Dja0))
Pr(Dja0)(aPr(Djai)z(1{a)(1{Pr(Djai))
~
Pr(Djai)((2a{1)Pr(Dja0)z1{a)
P(Dja0)((2a{1)Pr(Djai)z1{a)
From this, we get: Pr(Djai)~
(1{a)ORiPr(Dja0)
1{az(1{2a)Pr(Dja0)(ORi{1)
ð2Þ
Similar to Equation 1, we know that Pr(D)~
Pm
i~0
f iPr(Djai).
Therefore, by Equation 2, we get the following:
Pr(D)~
Xm
i~0
f i(1{a)ORiPr(Dja0)
1{az(1{2a)Pr(Dja0)(ORi{1)
For a fixed a, we can solve this equation using a binary search
on the variable Pr(D|a0); there is exactly one solution between 0
and Pr(D) since the right hand side of this equation is an increasing
function of Pr(D|a0) and binary search is guaranteed to find that
solution.
Generally, the value of a is unknown and it has to be
determined based on the age characteristics of the study
population. For instance, if the control population is a sample
from the general population, then a should be taken as the average
lifetime risk of the disease. However, if the control population was
chosen so that their age range is after the age of onset of the
disease, a should be close to 0. When case-control genotype data is
given, one can use maximum likelihood estimation to calculate a.
Calculating the GCI score
The GCI method essentially provides a way to compute the
relative risks of an individual as compared to an individual with
non-risk alleles at each of the disease-associated marker. In order
to calculate the lifetime risk, we take the product of the relative
risks across all loci (this is the overall relative risk of the individual
under the multiplicative model) and multiply it by the average
lifetime risk of the disease in the population. We then divide this
product by the average overall relative risk of the population. To
approximate the average relative risk of the population, we assume
that the SNPs at different loci are independent of one another (i.e.
in linkage equilibrium). Under this assumption, the average overall
relative risk of the population is equal to the product of the average
relative risks at each disease-associated marker.
If all the markers effects are independent, the relative risk of
individual i is equal to li~ P
n
j~1
lij where lij denotes the relative
risk for the jth locus. Let Pr(D) denote the average lifetime risk of
the disease in the population. Then, the GCI lifetime risk
probability or GCI score of an individual i is:
Pr(D) P
n
j~1
lij= P
n
j~1
(
Xk~m
k~0
fjkljk)
Here, m+1 alleles are possible at each marker locus and ljk
denotes the relative risk of the kth allele of the jth locus and fjk
denotes its frequency in the sample.
Theoretical Disease Models
We compared the GCI score to the optimal risk scores
calculated under two different theoretical disease models. These
models assume that the disease is affected by both environmental
and genetic factors, and that the two factors are independent of
each other. We denote the phenotype P~GzE, where G is the
genetic variable and E is the environmental variable. Our first
model assumes that both G and E are normally distributed with
standard deviations of sG and sE respectively, and that an
individual will develop the condition in his or her lifetime if
Pw afor a fixed a. Similar models have often been used when
heritability calculations are made [28]. We fix sG, sE and a using
the constraint that h~sG
2=(sG
2zsE
2), and that the average
lifetime risk is equal to Probability (Pwa). Since the heritabilities
and average lifetime risks are known for each of the conditions we
test, we can set the parameters of the models according to the
disease. For this disease model, we can analytically show that the
theoretical genetic maximum of AUC (i.e. when G is known but E
is unknown) only depends on the heritability and the average
lifetime risk of the disease (See next section) and not on the choice
of sG, sE, or a which are difficult to estimate.
In the second model, a variant of the previous model, we
assume that G~
P
liXizG1, where G1 is normally distributed
with standard deviation sG1, and Xi *B(2, pi) is Binomially
distributed. In this case, Xi corresponds to SNPs with large effects
and G1 represents many other small genetic effects; if there are
enough small genetic effects, we expect that the asymptotic
behavior of their sum would be according to a normal distribution.
By setting the parameters l, sG1 and p appropriately, we can
control the relative risks of the large effect SNPs. We tune these
parameters such that the relative risks are close to values observed
in Table 1 (see below). As for the previous model, we can show
that when G is known (but E is unknown) and the relative risks of
the large effect SNPs and risk-allele frequencies are fixed, the area
under the ROC curve for the second model only depends on the
heritability and the average lifetime risk of the disease (see below).
Proof for theoretical disease model 1
In this section, we will show that the theoretical genetic
maximum of the area under the ROC curve for model 1 depends
on the average lifetime risk (ALTR) and the heritability of the
disease alone. Let se denote the variance in the environmental
variable and sg denote the variance in the genetic variable. In
model 1, both genetic (G) and environmental (E) variables are
normally distributed. The theoretical maximum of ROC curve is
obtained when the genetic variable is known exactly while the
environmental variable is unknown. An individual is a true case if
GzEwaand a true control otherwise. For any cutoff chosen for
the genetic variable, the individuals who are above that cutoff will
be counted as cases and the rest as controls. The true positive
fraction (TPF) is the fraction of true cases that are called as cases
Lifetime Disease Risk
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and false positive fraction (FPF) is the fraction of true controls that
are called as cases. The TPF versus FPF for different values of
cutoffs gives us the ROC curve.
The probability that an individual’s genetic variable is greater
than some cutoff (c) is given by: P(Gw c)~
ð?
bsg
e{x
2=2sg
2
dx=ffiffiffiffiffi
2p
p
sg
where b~ c =s
g
.
The probability that an individual’s genetic variable is greater
than the cutoff and the individual is a true case is: P(Gw c and
GzEwa)~
ð?
bsg
e{x
2=2sg
2
(
ð?
c
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg2zse2
q
{x
e{y
2=2se
2
dy=
ffiffiffiffiffi
2p
p
se)dx=
ffiffiffiffiffi
2p
p
sg
where c~ a=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg2zs
p
e
2
. Note that for any non-zero average
lifetime risk, c is fixed because a increases linearly withffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg2zs
p
e
2
.
By definition heritability, h~sG
2=(sG
2zsE
2).
The integral within the brackets in the previous double integral
can be expressed in terms of the error function, erf. Because the
cumulative distribution function of normal distribution is given by
0:5(1zerf(y=
ffiffiffi
2
p
se)), the integral inside the brackets is
0:5{0:5erf(½c
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
s2gzs
2
e
q
{x= ffiffiffi2p se).
Thus, the probability that an individual is a true case and its
genetic variable is greater than c can expressed as:
ð?
bsg
e{x
2=2sg
2
(0:5{ 0:5erf(cf(h){g(h)x=
ffiffiffi
2
p
sg))dx=
ffiffiffiffiffi
2p
p
sg, where f(h) and
g(h) are some functions of the heritability. Substituting
t~ x=
ffiffiffi
2
p
sg into this equation, we can see that
ffiffiffi
2
p
sgdt~ dx.
Therefore, P (G.c and G+E.a) can be expressed as:
ð?
b=
ffiffiffi
2
p
e{t
2
(0:5{ 0:5erf(cf(h){g(h)t))dt=
ffiffiffi
p
p
Similarly, the probability that an individual is a true control and its
genetic variable is greater than c i.e. P(Gw c andGzEv~
a)~
ð?
b=
ffiffiffi
2
p
e{t
2
(0:5z0:5erf(cf(h){g(h)t))dt=
ffiffiffi
p
p
:
Therefore, the true positive fraction for any given b only depends
on h and ALTR since: TPF~P (Gw c andGzEw a)=ALTR.
The same is also true for false positive fraction since
FPF~P (Gw c andGzEv~ a)=(1 -ALTR). Hence, the to-
tal area under the theoretical ROC curve, which is based on TPF
and FPF at all possible values of b, is independent of se and sg.
Proof for theoretical disease model 2
In this section, we prove a result similar to that in the previous
section for disease model 2. In particular, we will show that if the
relative risks of SNPs known to be associated with a disease and
the risk-allele frequencies (pi) are fixed, then the theoretical genetic
maximum of the area under the ROC curve depends only on the
heritability and the average lifetime risk of the disease. In model 2,
the genetic variable is given by: G~
P
liXizG1. Here
G1*N(0,sg1)and the Xis are distributed according to a
Binomial distribution of B(2, pi), where pi is the allele frequency
of the risk allele at locus i. B(2, pi) gives the number of risk allele
copies in an individual at locus i. Xi~ 0means homozygous for
non-risk allele, Xi~ 1 means heterozygote and Xi~ 2 means
homozygous for risk allele. The normal variable represents the
unknown genetic component. As before, the environmental
variable E is also normally distributed with mean 0 and standard
deviation se. The phenotype is given by P~GzE and individuals
with Pw aare diseased whereas the rest are controls. a is chosen
such that the fraction of diseased individuals equals the average
lifetime risk of the disease.
Heritability for this model is h~ ½sg12 z
P
2li
2
pi(1 - pi)=½sg12 zse2 z
P
2li
2 pi(1 - pi) : Let us assume that
the relative risks of the known SNPs for heterozygous genotypes
are fixed and denote these by RNi. By definition, the relative risk
of heterozygote is given by:
RNi~Pr(GzEw a j Xi~ 1) =Pr(GzEw a jXi~0)
~ ½
X
Pr(G1zEw a - z - li)Pr(W~ z)=
½
X
Pr(G1zEwa - z)P(W~ z),
where W~
P
j1i
ljXj.
Let erf denote the error function and erfc denote the
complementary error function (i.e. 1 – erf(x)). Since G1+E is
N(0,
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
), the relative risk expressed in terms of
complementary error function is given by: S0.5erfc[(a - z - li)/ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2(sg12zse2)
p
]Pr(W~ z)/S0.5erfc[(a - z)/
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
2(sg12zse2)
p
)]
Pr(W~ z). Thus, if lis with disease cutoff a represent the
solutions for the SNPs for some choice of
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
, then Llis
with cutoff of La will necessarily be solutions if the standard
deviation of G1 and E get changed by a factor of L. This is
because z is always a linear combination of lis. Therefore, li/ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
and c~a=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
are independent offfiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
and depend on heritability and ALTR alone.
By definition, h(sg1
2zse
2)~ (1 - h)
P
2li
2 pi(1 - pi)zsg1
2.
This therefore means that: sg1
2 = (sg1
2zse
2)~h - (1-h)P
2li
2pi (1 - pi)= (sg1
2zse
2): Since li/
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
(sg12zse2)
p
and pi
are independent of
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
, sg1
2=(sg1
2zse
2) is a function
of heritability and ALTR alone. Let Z~
P
liXi and V denote
the vector of Xi values. Then, if Z~ z for V~ v,
z=
ffiffiffi
2
p
sg1~b(h,ALTR, v) is a function of the heritability, ALTR
and v alone and is independent of
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
.
The true positive fraction is defined as: Pr(G.c & G+E.a)/
Pr(G+E.a) where c denotes the cutoff for genetic variable. Let
b~ c =sg1. The numerator for TPF can be calculated as:P
Pr(V~v,Z~z)
ð?
bsg1{z
e{x
2=2sg1
2
(
ð?
c
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
q
{x{z
e{y
2=2se
2
dy=
ffiffiffiffiffi
2p
p
se)dx=
ffiffiffiffiffi
2p
p
sg1
Using the error function to express the cumulative distribution
function of the normal distribution, Pr(G.c & G+E.a) is:
X
Pr(V~v,Z~z)
ð?
bsg1{z
e
{x2=2sg1
2
(0:5{0:5erf ½r(h,ALTR,v)
{s(h,ALTR)x=
ffiffiffi
2
p
sg1)dx=
ffiffiffiffiffi
2p
p
sg1
where r and s are some functions. Substituting t~ x=
ffiffiffi
2
p
sg into
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this equation, we can see that
ffiffiffi
2
p
sgdt~ dx. Therefore, P (G.c
and G+E.a) can be expressed as:
X
Pr(V~v,Z~z)
ð?
(b=
ffiffiffi
2
p
){b(h,ALTR,v)
e{t
2
(0:5
{0:5erf ½r(h,ALTR,v){s(h,ALTR)t)dt= ffiffiffipp
Similarly, the probability that an individual is a true control and
its genetic variable is greater than c i.e.
P (Gw c andGzEv~a)~
X
Pr(V~v,Z~z)
ð?
(b=
ffiffiffi
2
p
){b(h,ALTR,v)
e{t
2
(0:5
z0:5erf ½r(h,ALTR,v){s(h,ALTR)t)dt= ffiffiffipp
Note that ALTR~P (GzEw a) and Pr(V~v, Z~z) is fixed
if pis are fixed. Therefore, the true positive fraction for any given b
only depends on the h and ALTR. The same is also true for false
positive fraction since FPF~Pr(Gw c andGzEv~a) =
(1 -ALTR). So, the area under the theoretical ROC curve,
which is based on TPF and FPF at all possible values of b, is
independent of se, sg1 and lis.
Solving for li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
We first note that 1 - (sg1
2=(h(sg1
2zse
2))) ~ (1-h)
P
2li
2pi
(1 - pi)=(h(sg1
2zse
2)). So, this equation implies that 0v~
li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
v~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
h=(2pi(1{pi)(1{h))
p
since LHS is always
less than 1. In practice, we can obtain a simultaneous solution for all
li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
by using the following iterative procedure:
Initially, determine the li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
for each SNP assuming
that it is the only SNP present (i.e. assuming lj~ 0 for
all j not equal to i using a binary search between 0 andffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
h=(2pi(1{pi)(1{h))
p
(Note that RNi increases with
li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
). These values will be our initial guesses for
li=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
. Then,
1) Determine l1=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
assuming that lj=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
for other SNPs are equal to what was calculated in the previous
step by using a binary search between 0 and
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½(h=(1{h)) {
X
j=1
2lj
2pj(1{pj)=(sg1
2zse2)=(2p1(1{p1))
s
:
2) Determine l2=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
assuming that lj=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
for other SNPs are equal to what was calculated in the previous
step by using a binary search between 0 and
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½(h=(1{h)){
X
j=2
2lj
2pj(1{pj)=(sg1
2zse2)=(2p2(1{p2))
s
:
……
n) Determine ln=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
assuming that lj=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
for other SNPs are equal to what was calculated in the previous
step by using a binary search between 0 and
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
½(h=(1{h)) {
X
j=n
2lj
2pj(1{pj)=(sg1
2zse2)=(2pn(1{pn))
s
:
If all RNj values are sufficiently close to the observed values,
stop. Else go back to step 1.
Simulation experiments indicated that the above heuristic
converges to a simultaneous solution for all lj=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
sg12zse2
p
whenever a solution exists.
Obtaining robust estimates of heritability and lifetime
risk from literature
Since heritability can vary by population, age, environmental
variation, phenotypic definition, sample size or standard error; we
sought multiple references and chose the most robust estimate
based on the method of calculating heritability, sample size,
ancestral origin and study population. If several articles had good
methodology, we tried to pick one ‘‘in the middle’’ of the range of
reported estimates. For lifetime risk, there is often not multiple
references and sometimes we relied on incidence data.
Obtaining lifetime risk estimates from Incidence data
When lifetime risk data was not available from the literature (for
Crohn’s disease and Rheumatoid Arthritis), we used incidence
data to obtain an estimate of the average lifetime risk (ALTR)
using a conversion formula. Namely, we used the following
formula:ALTR~ (N=ni) x incidence, where N represents the
total number of individuals in the US from the 1990 or 2000
census data depending on the study used to identify incidence, ni is
the number of live births in the US in the year 2000; each from the
appropriate gender and ethnicity. The main assumptions in this
formula are: 1. Fixed population size. 2. Maximum life span for all.
We first validated our formula to determine if incidence data
could incorrectly estimate lifetime risk using incidence and lifetime
risk data from the Surveillance Epidemiology and End Results of
the National Cancer Institute (USA) for a number of common
cancers. Using our calculation with incidence data we estimated
the published lifetime risk within 1% for breast, colon, prostate
and lung cancers (results not shown). Thus, we are confident that
our lifetime risk calculations are reliable.
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